logo
Plus   Neg
Share
Email

Novartis: Aimovig Shows Long-term Efficacy In Treatment Of Episodic Migraine

Novartis (NVS) reported positive results from a 4.5-year, interim analysis of a 5-year, open-label treatment period to evaluate Aimovig in patients with episodic migraine. In the study, Aimovig reduced monthly migraine days, and also lowered the number of days requiring acute migraine-specific medication. The safety profile and tolerability were in line with previous clinical data for Aimovig.

Aimovig is a EMA and FDA-approved migraine prevention treatment. Novartis and Amgen are co-commercializing Aimovig in the US. Amgen has rights to Aimovig in Japan. Novartis has rights to commercialize in the rest of the world.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients. Ferring Pharmaceuticals US is recalling various nasal sprays citing superpotency or amounts of desmopressin higher than specified, the U.S. Food and Drug Administration announced in a statement. The recall involves all lots on the market of DDAVP Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE Nasal Spray 1.5 mg/mL. U.S. President Donald Trump has issued executive orders to ban Chinese mobile application TikTok as well as WeChat, citing a threat to national security and its economy. China's ByteDance Ltd. owns TikTok, a video-sharing mobile app, while Tencent Holdings Ltd. owns WeChat, a messaging, social media, and electronic payment app.
Follow RTT